Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MCRB 
Seres Therapeutics Inc (MCRB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MCRB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.33
1 Year Target Price $13.33
| 2 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.15% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 79.47M USD | Price to earnings Ratio - | 1Y Target Price 13.33 |
Price to earnings Ratio - | 1Y Target Price 13.33 | ||
Volume (30-day avg) 5 | Beta 2.62 | 52 Weeks Range 6.53 - 30.60 | Updated Date 06/30/2025 |
52 Weeks Range 6.53 - 30.60 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.22% | Return on Equity (TTM) -1556.28% |
Valuation
Trailing PE - | Forward PE 4.84 | Enterprise Value 110164040 | Price to Sales(TTM) 390.27 |
Enterprise Value 110164040 | Price to Sales(TTM) 390.27 | ||
Enterprise Value to Revenue 805.87 | Enterprise Value to EBITDA -2.07 | Shares Outstanding 8732420 | Shares Floating 6436057 |
Shares Outstanding 8732420 | Shares Floating 6436057 | ||
Percent Insiders 13.01 | Percent Institutions 35.23 |
Analyst Ratings
Rating 3 | Target Price 13.33 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 2 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Seres Therapeutics Inc
Company Overview
History and Background
Seres Therapeutics, founded in 2010, pioneers microbiome therapeutics, focusing on developing treatments that modulate the gut microbiome to treat diseases. Key milestones include clinical trial successes for SER-109 (now VOWST) and platform technology advancements.
Core Business Areas
- Gastrointestinal Therapeutics: Focuses on developing microbiome-based therapies for gastrointestinal conditions, including recurrent C. difficile infection (rCDI).
- Platform Technology: Development and optimization of a proprietary microbiome therapeutics platform for identifying and engineering microbiome-based therapies.
Leadership and Structure
Eric Shaff (President and CEO). Structure includes research and development, clinical operations, manufacturing, and commercial functions.
Top Products and Market Share
Key Offerings
- VOWST (fecal microbiota spores, live-brpk): VOWST is an FDA-approved oral microbiome therapeutic for preventing recurrent Clostridioides difficile infection (rCDI) in adults following antibacterial treatment for rCDI. It is a capsule of bacteria that will attempt to recolonize the gut with healthy bacteria to prevent recurrance. Competitors include fecal microbiota transplantation (FMT) procedures. Market share data is still developing as the product recently launched.
Market Dynamics
Industry Overview
The microbiome therapeutics industry is rapidly evolving, with increasing recognition of the gut microbiome's role in various diseases. The market is driven by unmet medical needs and advances in microbiome research.
Positioning
Seres is a leader in the microbiome therapeutics space, with VOWST being the first FDA-approved oral microbiome therapeutic for rCDI. Competitive advantages include its proprietary platform technology and clinical expertise.
Total Addressable Market (TAM)
The total addressable market for microbiome therapeutics is estimated to be billions of dollars, with significant potential for growth as more therapies are developed and approved. Seres is positioned to capture a substantial portion of this market, especially within the rCDI segment.
Upturn SWOT Analysis
Strengths
- First FDA-approved oral microbiome therapeutic for rCDI
- Proprietary microbiome therapeutics platform
- Strong clinical data for VOWST
- Experienced management team
Weaknesses
- Limited commercial history
- Reliance on single product (VOWST) for near-term revenue
- Manufacturing complexities associated with microbiome therapies
- Ongoing need for significant R&D investment
Opportunities
- Expanding VOWST's market reach and indications
- Developing new microbiome therapies for other diseases
- Strategic partnerships with pharmaceutical companies
- Advancements in microbiome research and technology
Threats
- Competition from other microbiome therapies and traditional treatments
- Regulatory hurdles and changing guidelines
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- CRSP
- MRKR
- ARLP
Competitive Landscape
Seres has a first-mover advantage with VOWST, but faces competition from other companies developing microbiome therapies and traditional treatment approaches. Competitive advantages include its platform technology and clinical expertise. Disadvantages include its limited commercial history and reliance on a single product.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven primarily by research and development milestones and clinical trial progress. The recent FDA approval and commercial launch of VOWST represents a significant growth inflection point.
Future Projections: Future growth is expected to be driven by VOWST sales and the advancement of other pipeline candidates. Analyst estimates vary depending on market penetration assumptions and clinical trial outcomes.
Recent Initiatives: Commercial launch of VOWST. Continued investment in R&D pipeline. Expansion of manufacturing capacity.
Summary
Seres Therapeutics is a pioneering microbiome therapeutics company with the first FDA-approved oral therapy for recurrent C. difficile infection. VOWST's launch is promising, but the company must successfully execute its commercial strategy and diversify its pipeline. Challenges include competition, regulatory hurdles, and manufacturing complexities. Seres' proprietary platform and clinical expertise provide a strong foundation for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Seres Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
- FDA
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is an estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Seres Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2015-06-26 | President, CEO & Director Mr. Eric D. Shaff M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 103 | |
Full time employees 103 | |||
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.